| A Study About the Safety of ASP2767 and Whether it Helps People With Glaucoma-Related Optic Nerve Damage (NCT07770685) | Astellas Pharma Global Development, Inc. | 2026-08-31 |
| A Study of ASP2138 Together With Chemotherapy and Pembrolizumab in Adults With Gastric Cancer (NCT07673887) | Astellas Pharma Global Development, Inc. | 2026-06-30 |
| Enfortumab Vedotin in Combination With Pembrolizumab vs. Concurrent Chemoradiotherapy (cCRT) in People With Muscle Invasive Bladder Cancer (EV-309) (NCT07566156) | Astellas Pharma Global Development, Inc. | 2026-05-11 |
| A Study of ASP546C in Adults With Gastroesophageal Cancer, Pancreatic Cancer or Other Solid Tumors (NCT07488676) | Astellas Pharma Global Development, Inc. | 2026-05-04 |
| A Study to Compare Setidegrasib (ASP3082) With Docetaxel, in People With Non-small Cell Lung Cancer With a KRAS G12D Mutation (NCT07566052) | Astellas Pharma Global Development, Inc. | 2026-04-28 |
| A Study to Evaluate the Effectiveness and Safety of Setidegrasib, Given With Either mFOLFIRINOX or NALIRIFOX Chemotherapies, in People With Pancreatic Cancer (NCT07409272) | Astellas Pharma Global Development, Inc. | 2026-02-17 |
| A Study of ASP2998 Given by Itself and Given With Standard Therapies in People With Solid Tumors (NCT07287995) | Astellas Pharma Global Development, Inc. | 2026-02-05 |
| A Study to Learn How Fluconazole, Carbamazepine and Itraconazole Affect How the Body Processes ASP3082 in Healthy Adults (NCT07395024) | Astellas Pharma Global Development, Inc. | 2026-02-03 |
| A Study to Evaluate the Safety and Drug Levels of ASP5541 in Chinese Participants With Prostate Cancer (NCT07339267) | Astellas Pharma Global Development, Inc. | 2026-01-20 |
| A Study of ASP2138 Given Before Surgery, Then Chemotherapy After Surgery, in People With Pancreatic Ductal Cancer (NCT07024615) | Astellas Pharma Global Development, Inc. | 2025-10-16 |
| A Study of Zolbetuximab With Chemotherapy in Adults With Pancreatic Cancer (NCT06396091) | Astellas Pharma Global Development, Inc. | 2025-09-24 |
| A Study of Gilteritinib in Adults With Advanced ALK-positive Non-small Cell Lung Cancer (NSCLC) (NCT07140016) | Astellas Pharma Global Development, Inc. | 2025-09-22 |
| A Safety Study of Enfortumab Vedotin in Indian Adults With Urothelial Cancer (NCT06862219) | Astellas Pharma Global Development, Inc. | 2025-06-21 |
| A Phase 2 Study to Evaluate the Effects of ASP5541 in Participants With Prostate Cancer (NCT07005154) | Astellas Pharma Global Development, Inc. | 2025-06-19 |
| A Study to Confirm if Fezolinetant Helps Reduce Hot Flashes in Chinese Women Going Through Menopause (NCT06812754) | Astellas Pharma Global Development, Inc. | 2025-03-10 |
| A Study of ASP1893 in Adults With Advanced CLDN6-positive Solid Tumors (NCT06681870) | Astellas Pharma Global Development, Inc. | 2024-12-31 |
| Experiment to Assess Preferences for Novel Hormonal Therapy and Androgen-deprivation Therapy in Prostate Cancer Patients (NCT06500741) | Astellas Pharma Global Development, Inc. | 2024-11-22 |
| A Study to Find a Suitable Dose of ASP2802 in People With CD20-positive B-cell Lymphomas (NCT06248086) | Astellas Pharma Global Development, Inc. | 2024-09-06 |
| A Study to Evaluate the Effects of ASP5502 in Healthy Adults and Adults With Primary Sjögren's Syndrome (NCT06544642) | Astellas Pharma Global Development, Inc. | 2024-08-21 |
| A Study to Confirm if Fezolinetant Helps Reduce Hot Flashes in Women With Breast Cancer Who Are Having Hormone Therapy (NCT06440967) | Astellas Pharma Global Development, Inc. | 2024-07-31 |
| A Study of ASP1012 in Adults With Solid Tumors (NCT06171178) | Astellas Pharma Global Development, Inc. | 2024-05-15 |
| A Study to Find Out if ASP5354 Can Clearly Help Show the Ureter During Surgery in People With or Without Kidney Disease (NCT05999747) | Astellas Pharma Global Development, Inc. | 2024-03-19 |
| A Study to Learn How Effective and Safe the Drug 'Mirabegron' is and How Long it Stays in the Body of Children Aged 6 Months to Less Than 3 Years of Age With Neurogenic Detrusor Overactivity (NCT05621616) | Astellas Pharma Global Development, Inc. | 2024-02-28 |
| A Study of Roxadustat to Treat Anemia in Children and Teenagers With Chronic Kidney Disease (NCT05970172) | Astellas Pharma Global Development, Inc. | 2024-01-16 |
| A Study Following Women in Menopause Treated With a Non-hormonal Therapy for Hot Flashes and Night Sweats (NCT06049797) | Astellas Pharma Global Development, Inc. | 2023-11-15 |
| A Study to Find Out if ASP5354 Can Clearly Help Show the Ureter During Surgery (NCT05754333) | Astellas Pharma Global Development, Inc. | 2023-08-02 |
| XNW27011 Study of Advanced Solid Tumor Subjects Who Failed Standard Therapies. (NCT06792435) | Astellas Pharma Global Development, Inc. | 2023-07-27 |
| A Study of ASP1002 in Adults for Treatment of Solid Tumors (NCT05719558) | Astellas Pharma Global Development, Inc. | 2023-03-13 |
| A Study of ASP2074 in Adults With Solid Tumors (NCT05646797) | Astellas Pharma Global Development, Inc. | 2023-02-28 |
| A Study of Gilteritinib, Venetoclax and Azacitidine as a Combined Treatment for People Newly Diagnosed With Acute Myeloid Leukemia (NCT05520567) | Astellas Pharma Global Development, Inc. | 2023-01-31 |
| Incidence and Clinical Burden of Erythropoietin Hyporesponsiveness - a Retrospective Database Analysis (NCT05530291) | Astellas Pharma Global Development, Inc. | 2022-11-18 |
| A Study of ASP2138 Given by Itself or Given With Other Cancer Treatments in Adults With Stomach Cancer, Gastroesophageal Junction Cancer, or Pancreatic Cancer (NCT05365581) | Astellas Pharma Global Development, Inc. | 2022-06-07 |
| A Study to Find a Suitable Dose of ASP8731 and Check for Medical Problems at Each Dose in Healthy Adults (NCT05167526) | Astellas Pharma Global Development, Inc. | 2022-03-07 |
| A Study to Learn How [14C]ASP0367 is Processed by the Body in Healthy Men (NCT05217901) | Astellas Pharma Global Development, Inc. | 2022-01-21 |
| Study of ASP0739 Alone and With Pembrolizumab in Advanced Solid Tumors With NY-ESO-1 Expression Participants (NCT04939701) | Astellas Pharma Global Development, Inc. | 2021-12-23 |
| A Study of ASP0367 in People With Kidneys That do Not Work Well and in Healthy People (NCT05117294) | Astellas Pharma Global Development, Inc. | 2021-12-21 |
| A Study of Intravesical Enfortumab Vedotin For Treatment of Patients With Non-muscle Invasive Bladder Cancer (NMIBC) (NCT05014139) | Astellas Pharma Global Development, Inc. | 2021-12-07 |
| Study of ASP7517 Alone and With Pembrolizumab in Participants With Advanced Solid Tumors Expressing WT1 Antigen (NCT04837196) | Astellas Pharma Global Development, Inc. | 2021-11-11 |
| A Study of Fezolinetant to Treat Hot Flashes in Women Going Through Menopause (NCT05033886) | Astellas Pharma Global Development, Inc. | 2021-11-08 |
| A Study to Assess the Safety and Efficacy of ASP8062 as an Add-on Therapy to Buprenorphine/Naloxone in Participants With Opioid Use Disorder (NCT05062577) | Astellas Pharma Global Development, Inc. | 2021-11-08 |
| A Study of ASP1570 Taken by Itself, or ASP1570 Taken Together With Either Pembrolizumab, Standard Therapies, or Both, in Adults With Solid Tumors (NCT05083481) | Astellas Pharma Global Development, Inc. | 2021-10-19 |
| A Study to Evaluate ASP0367 in Participants With Mild/Moderate Hepatic Impairment Compared to Participants With Normal Hepatic Function (NCT04942964) | Astellas Pharma Global Development, Inc. | 2021-09-13 |
| Survey Based Discrete Choice Experiment Study in Prostate Cancer (DECIDER) Study (NCT05381311) | Astellas Pharma Global Development, Inc. | 2021-09-03 |
| A Safety and Dose-finding Study of PRL-02 Depot in Men With Advanced Prostate Cancer (NCT04729114) | Astellas Pharma Global Development, Inc. | 2021-06-14 |
| A Study to Evaluate ASP0367 in Participants With Reduced Maximum Oxygen Uptake Due to Poor Systemic Oxygen Extraction (NCT04855201) | Astellas Pharma Global Development, Inc. | 2021-06-14 |
| A Study to Investigate the Effect of Severe Renal Impairment on Gilteritinib Compared to Healthy Participants With Normal Renal Function (NCT04699877) | Astellas Pharma Global Development, Inc. | 2021-01-28 |
| A Study to Assess the Effect of Food With Fezolinetant in Healthy Female Participants (NCT04641260) | Astellas Pharma Global Development, Inc. | 2020-11-20 |
| A Study to Assess ASP0598 Otic Solution Following Topical Application in the Ear in Subjects With Chronic Tympanic Membrane Perforation (CTMP) (NCT04305184) | Astellas Pharma Global Development, Inc. | 2020-09-10 |
| A Study to Assess the Safety, Tolerability and Immunological Response of ASP2390 in Adult Subjects Allergic to House Dust Mites (NCT04184895) | Astellas Pharma Global Development, Inc. | 2020-09-09 |
| A Study of Gilteritinib (ASP2215) Combined With Chemotherapy in Children, Adolescents and Young Adults With FMS-like Tyrosine Kinase 3 (FLT3)/Internal Tandem Duplication (ITD) Positive Relapsed or Refractory Acute Myeloid Leukemia (AML) (NCT04240002) | Astellas Pharma Global Development, Inc. | 2020-09-04 |
| A Study to Investigate the Effect of Mild and Moderate Hepatic Impairment on the Safety and Tolerability of Fezolinetant Compared to Participants With Normal Hepatic Function (NCT04482270) | Astellas Pharma Global Development, Inc. | 2020-09-02 |
| A Study to Investigate the Effect of Renal Impairment on the Safety and Tolerability of Fezolinetant Compared to Participants With Normal Renal Function (NCT04476849) | Astellas Pharma Global Development, Inc. | 2020-08-10 |
| A Study to Assess the Safety, Tolerability and Pharmacokinetics of Multiple Doses of ASP8062 With a Single Dose of Morphine in Recreational Opioid Using Participants (NCT04448561) | Astellas Pharma Global Development, Inc. | 2020-06-30 |
| A Study to Assess the Effect of a Single Dose of ASP8062 on the Multiple Dose Safety, Tolerability and Pharmacokinetics of Buprenorphine/Naloxone in Participants With Opioid Use Disorder (NCT04447287) | Astellas Pharma Global Development, Inc. | 2020-06-29 |
| Enfortumab Vedotin and Pembrolizumab vs. Chemotherapy Alone in Untreated Locally Advanced or Metastatic Urothelial Cancer (NCT04223856) | Astellas Pharma Global Development, Inc. | 2020-03-30 |
| A Study to Evaluate Enfortumab Vedotin in Subjects With Locally Advanced or Metastatic Malignant Solid Tumors (EV-202) (NCT04225117) | Astellas Pharma Global Development, Inc. | 2020-03-10 |
| A Study to Assess Bioequivalence of Fezolinetant Formulations in Healthy Female Participants (NCT04277624) | Astellas Pharma Global Development, Inc. | 2020-02-20 |
| A Study to Evaluate the Effect of Multiple Doses of Enzalutamide on the Pharmacokinetics of Substrates of P-glycoprotein (Digoxin) and Breast Cancer Resistant Protein (Rosuvastatin) in Male Subjects With Prostate Cancer (NCT04094519) | Astellas Pharma Global Development, Inc. | 2020-01-27 |
| A Study to Assess Isavuconazole Following a Single Dose of Isavuconazonium Sulfate Intravenous Solution Via Nasogastric (NG) Tube Compared to a Single Dose of Oral Capsules Under Fasting Conditions in Healthy Participants (NCT04096157) | Astellas Pharma Global Development, Inc. | 2019-09-24 |
| Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ASP1617 in Healthy Adult Non-Asian and Japanese Subjects Including Assessment of a Food Effect (NCT04077879) | Astellas Pharma Global Development, Inc. | 2019-09-19 |
| A Study of an Intratumoral Oncolytic Virus in Patients With Advanced Metastatic Solid Tumors (NCT03954067) | Astellas Pharma Global Development, Inc. | 2019-09-03 |
| A Study to Evaluate Isavuconazonium Sulfate for the Treatment of Invasive Aspergillosis (IA) or Invasive Mucormycosis (IM) in Pediatric Participants (NCT03816176) | Astellas Pharma Global Development, Inc. | 2019-08-22 |
| A Study to Assess the Relative Bioavailability of Roxadustat Following a Single Dose of Pediatric Azo Dye-free Tablet Formulation and Pediatric Azo Dye-free Mini-tablet Formulation Compared to a Single Dose of Azo Dye-containing Tablet Formulation in Healthy Adult Subjects (NCT03960489) | Astellas Pharma Global Development, Inc. | 2019-07-31 |
| A Study to Assess Potential Interaction Between ASP8062 and Alcohol in Healthy Adult Subjects (NCT04003402) | Astellas Pharma Global Development, Inc. | 2019-07-16 |
| A Study to Find Out if Fezolinetant Helps Reduce Moderate to Severe Hot Flashes in Women Going Through Menopause (NCT04003155) | Astellas Pharma Global Development, Inc. | 2019-07-11 |
| A Study to Find Out How Safe Long-term Treatment With Fezolinetant is in Women With Hot Flashes Going Through Menopause (NCT04003389) | Astellas Pharma Global Development, Inc. | 2019-07-10 |
| A Study to Find Out if Fezolinetant Helps Reduce Moderate to Severe Hot Flashes in Women Going Through Menopause - 2 (NCT04003142) | Astellas Pharma Global Development, Inc. | 2019-07-10 |
| A Study to Assess ASP2713 in Healthy Subjects (NCT04017208) | Astellas Pharma Global Development, Inc. | 2019-07-01 |
| A Study of ASP2215 (Gilteritinib) Combined With Atezolizumab in Patients With Relapsed or Treatment Refractory FMS-like Tyrosine Kinase (FLT3) Mutated Acute Myeloid Leukemia (AML) (NCT03730012) | Astellas Pharma Global Development, Inc. | 2019-06-19 |
| A Study to Assess the Relative Bioavailability of Gilteritinib Following a Single Dose of Gilteritinib Mini-tablet Oral Suspension and Gilteritinib Mini-tablets Compared to a Single Dose of Gilteritinib Tablet in Healthy Subjects (NCT03964038) | Astellas Pharma Global Development, Inc. | 2019-05-21 |
| A Study to Assess the Safety and Efficacy of ASP1650, a Monoclonal Antibody Targeting Claudin 6 (CLDN6), in Male Subjects With Incurable Platinum Refractory Germ Cell Tumors (NCT03760081) | Astellas Pharma Global Development, Inc. | 2019-03-19 |
| A Study of Zolbetuximab (IMAB362) in Adults With Pancreatic Cancer (NCT03816163) | Astellas Pharma Global Development, Inc. | 2019-03-15 |
| A Study to Evaluate Safety, Tolerability and Immune Response in Adolescents Allergic to Peanut After Receiving Intradermal Administration of ASP0892 (ARA-LAMP-vax), a Single Multivalent Peanut (Ara h1, h2, h3) Lysosomal Associated Membrane Protein DNA Plasmid Vaccine (NCT03755713) | Astellas Pharma Global Development, Inc. | 2019-03-12 |
| A Study of ASP1951 in Subjects With Advanced Solid Tumors (NCT03799003) | Astellas Pharma Global Development, Inc. | 2019-01-14 |
| A Study in Healthy Adult Volunteers to Assess the Safety and Pharmacokinetics of an Investigational Imaging Product (NCT03698305) | Astellas Pharma Global Development, Inc. | 2018-10-25 |
| A Study to Assess the Safety and Efficacy of ASP4345 as Add-on Treatment for Cognitive Impairment in Subjects With Schizophrenia on Stable Doses of Antipsychotic Medication (NCT03557931) | Astellas Pharma Global Development, Inc. | 2018-07-13 |
| A Study of ASP1948, Targeting an Immune Modulatory Receptor as a Single Agent and in Combination With a PD-l Inhibitor (Nivolumab or Pembrolizumab) in Subjects With Advanced Solid Tumors (NCT03565445) | Astellas Pharma Global Development, Inc. | 2018-07-02 |
| A Study to Evaluate Enfortumab Vedotin Versus (vs) Chemotherapy in Subjects With Previously Treated Locally Advanced or Metastatic Urothelial Cancer (EV-301) (NCT03474107) | Astellas Pharma Global Development, Inc. | 2018-06-27 |
| A Study to Compare Zolbetuximab (IMAB362) and Chemotherapy With Placebo and Chemotherapy in Adults With Gastric Cancer. (NCT03504397) | Astellas Pharma Global Development, Inc. | 2018-06-21 |
| A Study to Assess the Safety, Tolerability, Pharmacodynamics and Pharmacokinetics of ASP6981 in Subjects With Schizophrenia (NCT03356639) | Astellas Pharma Global Development, Inc. | 2018-01-22 |
| Zimura Compared to Sham in Patients With Autosomal Recessive Stargardt Disease (STGD1) (NCT03364153) | Astellas Pharma Global Development, Inc. | 2018-01-12 |
| A Study of Enfortumab Vedotin Alone or With Other Therapies for Treatment of Urothelial Cancer (NCT03288545) | Astellas Pharma Global Development, Inc. | 2017-10-11 |
| A Study of Intravenous and Oral Isavuconazonium Sulfate in Pediatric Patients (NCT03241550) | Astellas Pharma Global Development, Inc. | 2017-10-02 |
| A Multiple-dose Study of ASP8374, an Immune Checkpoint Inhibitor, as a Single Agent and in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors (NCT03260322) | Astellas Pharma Global Development, Inc. | 2017-09-08 |